Abstracts tagged "COVID-19"

Abstract Number: 0109 • ACR Convergence 2021
COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Akhil Sood¹, Ronak Gandhi², Vijaya Murthy¹, Emilio Gonzalez³ and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX, ³University of Texas Medical Branch (utmb Health), Galveston, TX
Background/Purpose: Early studies published at the beginning of COVID-19 pandemic suggested lower risk of COVID-19 and less severe disease course in patients with rheumatic diseases…
Abstract Number: 0444 • ACR Convergence 2021
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Latika Gupta¹, James Lilleker², Vishwesh Agarwal³, Sinan Kardes⁴, Marcin Milchert⁵, Tamer Gheita⁶, Babur Salim⁷, Tsvetelina Velikova⁸, Oliver Distler⁹, Hector Chinoy¹⁰, Vikas Aggarwal¹ and Rohit Aggarwal¹¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, ³Mahatma Gandhi Mission Medical College, Navi Mumbai, India, ⁴Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, ⁶Cairo University, Egypt, Cairo, Egypt, ⁷Fauji Foundation Hospital, Rawalpindi, Pakistan, ⁸University Hospital Lozenetz, Sofia, Bulgaria, ⁹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁰University of Manchester, Salford, United Kingdom, ¹¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 1067 • ACR Convergence 2021
Experiences of Self-Care During the COVID-19 Pandemic Among Individuals with Rheumatoid Arthritis: A Qualitative Study
Jenny Leese¹, Catherine L. Backman¹, Jasmin Ma¹, Cheryl Koehn², Alison Hoens³, Kelly English³, Eileen Davidson⁴, Shanon McQuitty³, James Gavin⁵, Jo Adams⁵, Stephanie Thierren⁶ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²Arthritis Consumer Experts, Vancouver, BC, Canada, ³Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ⁴Arthritis Research Canada Arthritis Patient Advisory Board, Burnaby, BC, Canada, ⁵University of Southampton, Southampton, United Kingdom, ⁶Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: The COVID-19 pandemic poses new challenges for individuals with rheumatoid arthritis (RA) to manage their self-care, such as being physically active, maintaining emotional wellbeing,…
Abstract Number: 1524 • ACR Convergence 2021
COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population
Suguni Gallappaththy¹, Sarah Ifteqar² and Amr Edrees³, ¹University of Missouri Kansas City, Kansas City, KS, ²UMKC, Kansas City, MO, ³UMKC, Overland Park, KS
Background/Purpose: Patients with autoimmune inflammatory rheumatic disease (AIRD) are at a higher risk for serious infections due to a combination of disease related immune dysfunction…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…
Abstract Number: 1564 • ACR Convergence 2021
Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
Paola Estefania Bermudez Bermejo¹, RODOLFO JIMENEZ-SOTO¹, Alain Sanchez-Rodríguez¹, Alonso Turrent¹, Daniela Mercado- Velasco¹, Ian Bravo-Lee¹, Mariana Berenice Colli-Cortés², Everardo Alvarez Hernandez³ and MaryCarmen Amigo¹, ¹CENTRO MEDICO ABC, Mexico City, Mexico, ²Hospital Regional "General Ignacio Zaragoza" ISSSTE, Mexico City, Mexico, ³HOSPITAL GENERAL DE MEXICO, Mexico City, Mexico
Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls…
Abstract Number: 1605 • ACR Convergence 2021
Health Related Quality of Life in Rheumatology Outpatients with COVID-19 from New York City over the Course of the Pandemic
Lisa Mandl¹, Jonah Levine¹, Vivian Bykerk² and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: The impact of the COVID-19 pandemic on the mental and physical well-being of patients with systemic rheumatic diseases (SRDs) remains to be quantified. We…
Abstract Number: 1643 • ACR Convergence 2021
Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
Xinyu Dou¹, David Kaelber² and Hulya Bukulmez¹, ¹MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ²The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH
Background/Purpose: COVID-19, as a member of the Coronavirus family, has been described to trigger host immune response via type I interferon (IFN) signaling pathways with…
Abstract Number: 0093 • ACR Convergence 2021
The Association of General and Covid-19-Specific Stress with Changes in Patient-Reported Outcomes and Comorbidities
Patricia Katz¹, Kristin Wipfler², Sofia Pedro³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: We previously showed that perceived stress during the COVID-19 pandemic was associated with concomitant increases in symptoms of depression and anxiety. In lupus alone,…
Abstract Number: 0110 • ACR Convergence 2021
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Kaleb Michaud¹, Sofia Pedro², Rebecca Schumacher³, Mukund Kumar¹, Bryant England¹ and Alison Freifeld¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Forward Databank, Wichita
Background/Purpose: Recent studies have detailed the excess death due to COVID-19 during the pandemic, yet few have examined these rates within a rheumatic disease population…
Abstract Number: 0457 • ACR Convergence 2021
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
Michael Paley¹, Parakkal Deepak², Wooseob Kim², Monica Yang³, Alex Carividi³, Emanuel Demissie³, Alia A. El-Qunni,², Alem Haile², Katherine Huang², Baylee Kinnett², Mariel Liebeskind², Zhouming Liu², Lily E. McMorrow², Diana Paez³, Niti Pawar³, Dana Perantie², Rebecca E. Schriefer², Shannon Sides², Mahima Thapa², Sewuese Akuse⁴, Samantha Burdess², Abbey Rose², Lynne Mitchell², Salim Chahin², Matthew Ciorba², Jonathan Graf⁵, Patricia Katz³, Mehrdad Matloubian³, Jane O'Halloran², Rachel Presti², Gregory Wu², Sean Whelan², William Buchser², Lianne Gensler⁶, Mary Nakamura⁷, Ali H Ellebedy² and Alfred Kim², ¹Washington University in St. Louis, Olivette, MO, ²Washington University School of Medicine, St. Louis, MO, ³University of California San Francisco, San Francisco, CA, ⁴Washington University School of Medicine, St Louis, MO, ⁵Ucsf, San Francisco, CA, ⁶Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁷UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
Abstract Number: 0880 • ACR Convergence 2021
Health Information Use by SLE Patients Pre and During COVID-19
Francesca Cardwell¹, Susan Elliott², May Choi³, Ricky Chin³, Yvan St.Pierre⁴, Leigha Rowbottom⁵, Murray Urowitz⁶, Guillermo Ruiz-Irastorza⁷, Sasha Bernatsky⁸, Michelle Petri⁹, Susan Manzi¹⁰, Christine Peschken¹¹, Rosalind Ramsey-Goldman¹², Paul R Fortin¹³, Jungmin Shin¹⁴, Sang-Cheol Bae¹⁵, Jiacai Cho¹⁶, Anselm Mak¹⁷, John Hanly¹⁸, Anca Askanase¹⁹, Juanita Romero-Diaz²⁰, Romina Nieto²¹, Bernardo A. Pons-Estel²², Ian N. Bruce²³, Daniel Wallace²⁴ and Ann Clarke⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁷Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ⁸McGill University, Montréal, QC, Canada, ⁹Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Allegheny Health Network, Wexford, PA, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Northwestern University, Chicago, IL, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Hanyang University Hospital, Seoul, Republic of Korea, ¹⁵Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁶National University Health System (NUHS), Singapore, Singapore, ¹⁷National University of Singapore, Singapore, Singapore, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Columbia University Medical Center, New York, NY, ²⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ²¹Hospital Provincial de Rosario, Rosario, Argentina, ²²Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ²³University of Manchester, Manchester, United Kingdom, ²⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: The spread of COVID-19 misinformation is especially serious for individuals with complex diseases like SLE; conflicting and/or unfounded information can complicate a patient’s health…
Abstract Number: 1083 • ACR Convergence 2021
Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
Samira Nazzar Romero¹, Lakshmi Moorthy², Jennifer Tousseau³, Sivia Lapidus⁴, Mariana Correia Marques⁵, Leanne Mansfield⁶, Marinka Twilt⁷, Grant Schulert⁸, Maria Gutierrez⁹, Saskya Angevare¹⁰, Fatma Dedeoglu¹¹ and Karen Durrant¹², ¹University of California Los Angeles, Los Angeles, CA, ²Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Autoinflamamtory Alliance, Lincoln, CA, ⁴The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, ⁵UPMC Children`s Hospital of Pittsburgh, Pittsburgh, PA, ⁶Hospital for Special Surgery, New York, NY, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹John's Hopkins, Baltimore, MD, ¹⁰Autoinflammatory Alliance / Kaisz / ENCA as patient organizations, Amersfoort, Netherlands, ¹¹Boston Children's Hospital, Boston, MA, ¹²Autoinflammatory Alliance, San Francisco, CA
Background/Purpose: The exaggerated inflammatory responses to the SARS-CoV-2 virus and the paucity of data on COVID-19 infection risk in systemic autoinflammatory disease (SAID) patients posed…
Abstract Number: 1530 • ACR Convergence 2021
Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
Simón Ángel Sánchez-Fernández¹, Luisa Marena Rojas Vargas¹, Leticia Del Olmo Pérez², Paula Virginia García Morales¹, Adela Alía Jiménez¹, José Antonio Carrasco Fernández¹ and Sandra Masegosa Casanova³, ¹Hospital La Mancha Centro, Alcázar de San Juan, Spain, ²Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ³Hospital General de Tomelloso, Tomelloso, Spain
Background/Purpose: To assess whether two different biological therapies (BT), tumor necrosis factor inhibitor (TNFi) and ritixumab (RTX), are related to a different course and severity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].